EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transcriptomic and Clinical Profiling Reveals LGALS3 as a Prognostic Oncogene in Pancreatic Cancer

Grazia Scuderi, Sanja Mijatovic iD, Danijela Maksimovic-Ivanic iD, Michelino Di Rosa iD, José Francisco Muñoz-Valle iD, Alexis Missael Vizcaíno-Quirarte iD, Gian Marco Leone iD, Katia Mangano iD, Paolo Fagone iD, Ferdinando Nicoletti iD

Genes · 2025

DOI: 10.3390/genes16101170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Grazia Scuderi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Galectin 3, Transcriptome, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science, Technological Development and Innovation of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Galectin-3 (Gal-3), encoded by LGALS3, is a β-galactoside-binding lectin involved in diverse tumor-associated processes, including immune modulation, cell cycle regulation, and stress adaptation. Despite its known roles in cancer biology, the full extent of its molecular functions and prognostic relevance across tumor types remains incompletely understood. This study aimed to systematically investigate the transcriptomic impact of LGALS3 deletion and assess its clinical significance in cancer.

Methods

We analyzed CRISPR-Cas9 knockout transcriptomic data from the SigCom LINCS database to characterize the consensus gene signature associated with LGALS3 loss using functional enrichment analyses. Pan-cancer survival analyses were conducted using TIMER2.0. Differential Gal-3 protein levels in ductal adenocarcinoma and normal pancreatic tissues were evaluated using the Human Protein Atlas. Finally, functional analyses were performed in pancreatic ductal adenocarcinoma (PDAC).

Results

LGALS3 deletion across multiple cancer cell lines led to transcriptomic changes involving mitotic progression, stress responses, and axonal guidance pathways. High LGALS3 expression was significantly associated with worse overall survival in lower-grade glioma, PDAC, uveal melanoma, and kidney renal papillary cell carcinoma. LGALS3 knockout in YAPC cells recapitulated the pan-cancer findings, linking LGALS3 to cell morphogenesis and proliferation.

Conclusions

These findings identify Galectin-3 as a key regulator of oncogenic programs and a potential prognostic biomarker in PDAC and other malignancies, with implications for therapeutic targeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsGalectin 3TranscriptomeCarcinoma, Pancreatic DuctalBiomarkers, TumorOncogenesHumansPrognosisGene Expression Regulation, NeoplasticCell Line, TumorGene Expression ProfilingBlood ProteinsGalectins

Stichwörter der Autor:innen

LGALS3galectinsprognostic biomarkertranscriptomics

Substanzen

Galectin 3LGALS3 protein, humanBiomarkers, TumorBlood ProteinsGalectins

Autor:innen und Institutionen

  • Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
  • Department of Immunology, Institute for Biological Research "Sinisa Stankovic", Belgrade University, 11060 Belgrade, Serbia.
  • Department of Molecular Biology and Genomics, University Center of Health Sciences, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.
  • Department of Basic Psychology, University Center of Health Sciences, University of Guadalajara, Guadalajara 44340, Jalisco, Mexico.

ORCID-Profile: Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michelino Di Rosa, José Francisco Muñoz-Valle, Alexis Missael Vizcaíno-Quirarte, Gian Marco Leone, Katia Mangano, Paolo Fagone, Ferdinando Nicoletti

Förderung

  • Ministry of Science, Technological Development and Innovation of the Republic of Serbia

Zitieren

APA

Scuderi, G., Mijatovic, S., Maksimovic-Ivanic, D., Di Rosa, M., Muñoz-Valle, J. F., Vizcaíno-Quirarte, A. M., Leone, G. M., Mangano, K., Fagone, P., & Nicoletti, F. (2025). Transcriptomic and Clinical Profiling Reveals LGALS3 as a Prognostic Oncogene in Pancreatic Cancer. Genes. https://doi.org/10.3390/genes16101170

Vancouver

Scuderi G, Mijatovic S, Maksimovic-Ivanic D, Di Rosa M, Muñoz-Valle JF, Vizcaíno-Quirarte AM, et al. Transcriptomic and Clinical Profiling Reveals LGALS3 as a Prognostic Oncogene in Pancreatic Cancer. Genes. 2025. doi:10.3390/genes16101170

BibTeX
@article{Scuderi2025,
  author = {Scuderi, Grazia and Mijatovic, Sanja and Maksimovic-Ivanic, Danijela and Di Rosa, Michelino and Muñoz-Valle, José Francisco and Vizcaíno-Quirarte, Alexis Missael and Leone, Gian Marco and Mangano, Katia and Fagone, Paolo and Nicoletti, Ferdinando},
  title = {Transcriptomic and Clinical Profiling Reveals LGALS3 as a Prognostic Oncogene in Pancreatic Cancer},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16101170}
}
Kostenlos starten →